Saltar al contenido
Merck

Analysis of expression, epigenetic, and genetic changes of HNF1B in 130 kidney tumours.

Scientific reports (2020-10-15)
Michaela Bártů, Jan Hojný, Nikola Hájková, Romana Michálková, Eva Krkavcová, Ladislav Hadravský, Lenka Kleissnerová, Quang Hiep Bui, Ivana Stružinská, Kristýna Němejcová, Otakar Čapoun, Monika Šlemendová, Pavel Dundr
RESUMEN

Hepatocyte nuclear factor 1 beta (HNF1B) is a transcription factor which plays a crucial role in nephronogenesis, and its germline mutations have been associated with kidney developmental disorders. However, the effects of HNF1B somatic exonic mutations and its role in the pathogenesis of kidney tumours has not yet been elucidated. Depending on the type of the tumour HNF1B may act as a tumour suppressor or oncogene, although the exact mechanism by which HNF1B participates in the process of cancerogenesis is unknown. Using an immunohistochemical approach, and methylation and mutation analysis, we have investigated the expression, epigenetic, and genetic changes of HNF1B in 130 cases of renal tumours (121 renal cell carcinomas, 9 oncocytomas). In the subset of clear cell renal cell carcinoma (ccRCC), decreased HNF1B expression was associated with a higher tumour grade and higher T stage. The mutation analysis revealed no mutations in the analysed samples. Promoter methylation was detected in two ccRCCs and one oncocytoma. The results of our work on a limited sample set suggest that while in papillary renal cell carcinoma HNF1B functions as an oncogene, in ccRCC and chRCC it may act in a tumour suppressive fashion.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-HNF1B antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution